RSV immunization 97% effective against ICU admission in infants, study finds
A study published in JAMA Network Open found that the nirsevimab immunization is 97% effective at preventing ICU admissions for infants with RSV. The research highlights the success of universal immunization programs in Canadian provinces.
Why it matters
This data supports the efficacy of universal RSV prevention strategies, which could significantly reduce infant mortality and hospital strain during peak seasons.
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain A new immunization, offered free to all infants through universal programs in two Canadian provinces, provided strong protection against respiratory syncytial virus, commonly referred to as RSV, sharply reducing hospitalizations and intensive care unit (ICU) admissions in infants.
The findings, published in JAMA Network Open, evaluated the real-world effectiveness of nirsevimab, a long-acting monoclonal antibody that gives infants ready-made antibodies to prevent severe RSV illness. The research was conducted by the University of Calgary–led Surveillance Program for the Rapid identification and tracking of Infectious Diseases in kids (SPRINT-KIDS).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in